Oxford, UK, 5 April 2012, Summit (AIM: SUMM), a UK drug discovery company, today announces that the Circular to Shareholders and Notice of General Meeting (‘Circular’) have been posted to shareholders. Copies of the Circular will shortly be available on the Company's website, www.summitplc.com.
The General Meeting will be held at 10:00am on Friday 20 April 2012 at the offices of Fasken Martineau LLP, 17 Hanover Square, London W1S 1HU.
For more information, please contact:
Glyn Edwards / Richard Pye
Tel: +44 (0)1235 443 939
Singer Capital Markets
(Nominated Adviser and Joint broker)
Shaun Dobson / Claes Spång
Tel: +44 (0)203 205 7500
Claire Louise Noyce / Deepak Reddy
Tel: +44 (0)207 947 4350
(Financial public relations)
Tel: +44 (0)7879 458 364
Summit is an Oxford, UK based drug discovery Company with an innovative Seglin™ technology platform for the discovery of new medicines and a portfolio of drug programme assets. Summit’s programme portfolio consists of a number of drug programmes targeting high-value areas of unmet medical need including Duchenne Muscular Dystrophy and C. difficile infection. Summit is listed on the AIM market of the London Stock Exchange and trades under the ticker symbol SUMM.
Further information is available at www.summitplc.com.